Rehabilitation Enablement in Chronic Heart Failure—a facilitated self-care rehabilitation intervention in patients with heart failure with preserved ejection fraction (REACH-HFpEF) and their caregivers: rationale and protocol for a single-centre pilot randomised controlled trial

TY - JOUR

T1 - Rehabilitation Enablement in Chronic Heart Failure—a facilitated self-care rehabilitation intervention in patients with heart failure with preserved ejection fraction (REACH-HFpEF) and their caregivers

T2 - rationale and protocol for a single-centre pilot randomised controlled trial

AU - Eyre, V.

AU - Lang, C. C.

AU - Smith, K.

AU - Jolly, K.

AU - Davis, R.

AU - Hayward, C.

AU - Wingham, J.

AU - Abraham, C.

AU - Green, C.

AU - Warren, F. C.

AU - Britten, N.

AU - Greaves, C. J.

AU - Doherty, P.

AU - Austin, J.

AU - Van Lingen, R.

AU - Singh, S.

AU - Buckingham, S.

AU - Paul, K.

AU - Taylor, R. S.

AU - Dalal, H. M.

AU - REACH-HF investigators

N1 - This paper presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (Grant Reference Number RP-PG-1210-12004). NB, CA, CJG and RST are also supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) South West Peninsula at the Royal Devon and Exeter NHS Foundation Trust; KJ by CLAHRC West Midlands and SS by CLAHRC East-Midlands. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

PY - 2016/10/25

Y1 - 2016/10/25

N2 - Introduction: The Rehabilitation EnAblement in CHronic Heart Failure in patients with Heart Failure (HF) with preserved ejection fraction (REACH-HFpEF) pilot trial is part of a research programme designed to develop and evaluate a facilitated, home-based, selfhelp rehabilitation intervention to improve self-care and quality of life (QoL) in heart failure patients and their caregivers. We will assess the feasibility of a definitive trial of the REACH-HF intervention in patients with HFpEF and their caregivers. The impact of the REACHHF intervention on echocardiographic outcomes and bloodborne biomarkers will also be assessed. Methods and analysis: A single-centre parallel twogroup randomised controlled trial (RCT) with 1:1 individual allocation to the REACH-HF intervention plus usual care (intervention) or usual care alone (control) in 50 HFpEF patients and their caregivers. The REACHHF intervention comprises a REACH-HF manual with supplementary tools, delivered by trained facilitators over 12 weeks. A mixed methods approach will be used to assess estimation of recruitment and retention rates; fidelity of REACH-HF manual delivery; identification of barriers to participation and adherence to the intervention and study protocol; feasibility of data collection and outcome burden. We will assess the variance in study outcomes to inform a definitive study sample size and assess methods for the collection of resource use and intervention delivery cost data to develop the cost-effectiveness analyses framework for any future trial. Patient outcomes collected at baseline, 4 and 6 months include QoL, psychological well-being, exercise capacity, physical activity and HF-related hospitalisation. Caregiver outcomes will also be assessed, and a substudy will evaluate impact of the REACH-HF manual on resting global cardiovascular function and bloodborne biomarkers in HFpEF patients. Ethics and dissemination: The study is approved by the East of Scotland Research Ethics Service (Ref:15/ES/0036). Findings will be disseminated via journals and presentations to clinicians, commissioners and service users. Trial registration number: ISRCTN78539530; Pre-results .

AB - Introduction: The Rehabilitation EnAblement in CHronic Heart Failure in patients with Heart Failure (HF) with preserved ejection fraction (REACH-HFpEF) pilot trial is part of a research programme designed to develop and evaluate a facilitated, home-based, selfhelp rehabilitation intervention to improve self-care and quality of life (QoL) in heart failure patients and their caregivers. We will assess the feasibility of a definitive trial of the REACH-HF intervention in patients with HFpEF and their caregivers. The impact of the REACHHF intervention on echocardiographic outcomes and bloodborne biomarkers will also be assessed. Methods and analysis: A single-centre parallel twogroup randomised controlled trial (RCT) with 1:1 individual allocation to the REACH-HF intervention plus usual care (intervention) or usual care alone (control) in 50 HFpEF patients and their caregivers. The REACHHF intervention comprises a REACH-HF manual with supplementary tools, delivered by trained facilitators over 12 weeks. A mixed methods approach will be used to assess estimation of recruitment and retention rates; fidelity of REACH-HF manual delivery; identification of barriers to participation and adherence to the intervention and study protocol; feasibility of data collection and outcome burden. We will assess the variance in study outcomes to inform a definitive study sample size and assess methods for the collection of resource use and intervention delivery cost data to develop the cost-effectiveness analyses framework for any future trial. Patient outcomes collected at baseline, 4 and 6 months include QoL, psychological well-being, exercise capacity, physical activity and HF-related hospitalisation. Caregiver outcomes will also be assessed, and a substudy will evaluate impact of the REACH-HF manual on resting global cardiovascular function and bloodborne biomarkers in HFpEF patients. Ethics and dissemination: The study is approved by the East of Scotland Research Ethics Service (Ref:15/ES/0036). Findings will be disseminated via journals and presentations to clinicians, commissioners and service users. Trial registration number: ISRCTN78539530; Pre-results .

U2 - 10.1136/bmjopen-2016-012853

DO - 10.1136/bmjopen-2016-012853

M3 - Article

C2 - 27798024

SN - 2044-6055

VL - 6

SP - 1

EP - 11

JO - BMJ Open

JF - BMJ Open

IS - 10

M1 - e012853

ER -